Facts vs Fiction: the Role of Cannabinoids in the Treatment of Glaucoma
Tóm tắt
Từ khóa
Tài liệu tham khảo
Bridgeman MB, Abazia DT. Medicinal cannabis: history, pharmacology, and implications for the acute care setting. Pharm Ther. 2017;42(3):180–8.
Courtwright D. The controlled substances act: how a “big tent” reform became a punitive drug law. Drug Alcohol Depend. 2004;76:9–15.
Whiting P, Wolff R, Deshpande S, Nisio M, Duffy S, Hernandez A, et al. Cannabinoids for medical use. J Am Med Assoc. 2015;313:2456–73.
•• Atakan Z. Cannabis, a complex plant: different compounds and different effects on individuals. Ther Adv Psychopharmacol. 2012;2:241–54. Excellent summary of cannabinoids and the endocannabinoid system.
Lu Y, Anderson H. Cannabinoid signaling in health and disease. Can J Physiol Pharmacol. 2017;95:311–27.
Pertwee R. The pharmacology of cannabinoid receptors and their ligands: an overview. Int J Obes. 2006;30:S13–S8.
Delta-8-tetrahydrocannabinol. NCI Drug Dictionary 2018.
Cannabinol. PubChem Open Chemistry Database 2018.
Helper R, Frank I, Petrus R. Ocular effects of marihuana smoking. In: Barude S, editor. The pharmacology of marihuana. New York: Raven Press; 1976. p. 815–26.
Porcella A, Maxia C, Gessa GL, Pani L. The synthetic cannabinoid WIN55212-2 decreases the intraocular pressure in human glaucoma resistant to conventional therapies. Eur J Neurosci. 2001;13:409–12.
Green K, Bowman K. Effect of marihuana and derivatives on aqueous humor dynamics in the rabbit. In: The Pharmacology of Marihuana. New York: Raven Press; 1976. p. 803–14.
Straiker A, Maguire G, Mackie K, Lindsey J. Localization of cannabinoid CB1 receptors in the human anterior eye and retina. Invest Ophthalmol Vis Sci. 1999;40:2442–8.
Hingorani T, Gul W, ElSohly M, Repka M, Majumdar S. Effect of ion-pairing on in vitro transcorneal permeability of a Δ9- tetrahydrocannabinol prodrug: potential in glaucoma therapy. J Pharm Sci. 2012;101:616–26.
He F, Song ZH. Molecular and cellular changes induced by the activation of CB2 cannabinoid receptors in trabecular meshwork cells. Mol Vis. 2007;13:1348–56.
Jaanuleviciene I, Siaudvytyte L, Barsauskaite R. Ophthalmic drug delivery in glaucoma - a review. Pharmaceutics. 2012;4:243–51.
Green K, Bigger J, Kim K, Bowman K. Cannabinoid penetration and chronic effects in the eye. Exp Eye Res. 1977;24:197–205.
Green K, Roth M. Ocular effects of topical administration of Δ9-tetrahydrocannabinol in man. Arch Ophthalmol. 1982;100:265–7.
Jay W, Green K. Multiple-drop study of topically applied 1% Δ9-tetrahydrocannabinol in human eyes. Arch Ophthalmol. 1983;101:591–3.
Kearse EC, Green K. Effect of vehicle upon in vitro transcorneal permeability and intracorneal content of ∆9-tetrahydrocannabinol. Curr Eye Res. 2000;20:496–501.
Loftsson T, Stefansson E. Cyclodextrins in eye drop formulations: enhanced topical delivery of corticosteroids to the eye. Acta Ophthalmol Scand. 2002;80:144–50.
•• Adelli G, Bhagav P, Taskar P, Hingorani T, Pettaway S, Gul W, et al. Development of a Δ9-tetrahydrocannabinol amino acid-dicarboxylate prodrug with improved ocular bioavailability. Invest Ophthalmol Vis Sci. 2017;58:2167–79 Recent study looking at ways to improve corneal penetration with a lot of good background.
Kabiri M, Kamal S, Pawar S, Roy P, Derakhshandeh M, Kumar U, et al. A stimulus-responsive, in situ-forming, nanoparticle-laden hydrogel for ocular drug delivery. Drug Deliv Transl Res. 2018;8:484–95.
Sena D, Lindsley K. Neuroprotection for treatment of glaucoma in adults. Cochrane Database Syst Rev. 2018;1:CD006539.